Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Langman

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Kidney International|September 5, 2021
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaBernd Hoppe, Annelize Koch, Pierre Cochat, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 1, 1993
Bone disease in burn patientsG L Klein, D N Herndon, T C Rutan, et al.
Pediatric Nephrology (Berlin, Germany)|June 21, 2019
Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapyYusuke Okuda, Yoshitsugu Obi, Elani Streja, et al.
Arthritis and Rheumatism|October 1, 2009
25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosusPeggy W Wu, Elisa Y Rhew, Alan R Dyer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 28, 2014
Medication adherence and growth in children with CKDOleh M Akchurin, Michael F Schneider, Lucy Mulqueen, et al.
Journal of Endourology|February 19, 2020
Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus StatementBrian H Eisner, David S Goldfarb, Michelle A Baum, et al.
The Journal of Pediatrics|June 21, 2014
Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrateCraig B Langman, Larry A Greenbaum, Paul Grimm, et al.
Implementation Science Communications|August 25, 2020
Optimizing the implementation of a population panel management intervention in safety-net clinics for pediatric hypertension (The OpTIMISe-Pediatric Hypertension Study)Justin D Smith, Nivedita Mohanty, Matthew M Davis, et al.
Pediatric Nephrology (Berlin, Germany)|February 10, 2009
A position statement on kidney disease from powdered infant formula-based melamine exposure in Chinese infantsCraig B Langman, Uri Alon, Julie Ingelfinger, et al.
Kidney International|January 5, 2000
Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuriaS J Scheinman, J P Cox, S E Lloyd, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Kidney International|September 5, 2021
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaBernd Hoppe, Annelize Koch, Pierre Cochat, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 1, 1993
Bone disease in burn patientsG L Klein, D N Herndon, T C Rutan, et al.
Pediatric Nephrology (Berlin, Germany)|June 21, 2019
Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapyYusuke Okuda, Yoshitsugu Obi, Elani Streja, et al.
Arthritis and Rheumatism|October 1, 2009
25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosusPeggy W Wu, Elisa Y Rhew, Alan R Dyer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 28, 2014
Medication adherence and growth in children with CKDOleh M Akchurin, Michael F Schneider, Lucy Mulqueen, et al.
Journal of Endourology|February 19, 2020
Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus StatementBrian H Eisner, David S Goldfarb, Michelle A Baum, et al.
The Journal of Pediatrics|June 21, 2014
Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrateCraig B Langman, Larry A Greenbaum, Paul Grimm, et al.
Implementation Science Communications|August 25, 2020
Optimizing the implementation of a population panel management intervention in safety-net clinics for pediatric hypertension (The OpTIMISe-Pediatric Hypertension Study)Justin D Smith, Nivedita Mohanty, Matthew M Davis, et al.
Pediatric Nephrology (Berlin, Germany)|February 10, 2009
A position statement on kidney disease from powdered infant formula-based melamine exposure in Chinese infantsCraig B Langman, Uri Alon, Julie Ingelfinger, et al.
Kidney International|January 5, 2000
Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuriaS J Scheinman, J P Cox, S E Lloyd, et al.
Pageof 19